AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option.
Latest Information Update: 12 Mar 2021
At a glance
- Drugs SRA 515 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms AMLM22/D3
- Sponsors AstraZeneca
- 11 Mar 2021 New trial record